NYSE · TMO
Thermo Fisher Scientific Inc.
$709.18+$5.03 (+0.71%)
Thermo Fisher Scientific Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.38% below the high.
Loading market information…
NYSE · RVTY · USD
Stock price, dividends, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Revvity, Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.94% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Revvity, Inc.’s forward annual dividend is $0.28 per share, paid quarterly. The forward yield is 0.17% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Revvity, Inc.’s next earnings report is currently expected on Nov 3, 2026, with estimated earnings per share of $1.30. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Revvity, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Revvity, Inc., founded in 1937 and based in Waltham, Massachusetts, is a global enterprise that develops and delivers a wide array of products, services, and solutions. The company, which changed its name from PerkinElmer, Inc. in April 2023, caters to the diagnostics, life sciences, and applied services sectors worldwide. Its Discovery & Analytical Solutions division provides advanced instrumentation, reagents, informatics, software, subscriptions, and sophisticated detection and imaging technologies. These resources are designed to enable scientists to achieve significant breakthroughs in life sciences research. This segment also offers contract research and specialized laboratory services. Furthermore, it supplies analytical tools and services for assessing environmental health, including air, water, and soil, and delivers solutions to agricultural and food producers. It also serves the industrial market with analytical instrumentation for sectors such as chemical, semiconductor, electronics, energy, lubricants, petrochemicals, and polymers. The Diagnostics segment is dedicated to early detection, offering instruments, reagents, assay platforms, and software for identifying genetic disorders in pregnant individuals and young children, alongside infectious disease testing. Its products facilitate the screening of genetic abnormalities, disorders, and diseases like Down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This division also innovates technologies that support genomic workflows, leveraging protein-coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. Revvity serves a diverse clientele, including pharmaceutical and biotechnology firms, laboratories, academic and research institutions, public health authorities, private healthcare organizations, medical professionals, and government bodies.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 01:04 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q1 2025 |
|---|
| Apr 28, 2025 |
| $1.01+5.21% vs estimate |
| $664.76M-6.48% vs estimate |
| Q4 2024 | Jan 31, 2025 | $1.42+3.65% vs estimate | $729.37M+9.63% vs estimate |
|---|
| Q3 2024 | Nov 4, 2024 | $1.28+13.27% vs estimate | $684.05M+0.65% vs estimate |
|---|
THE ANALYST VIEW
29 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 8 contributors · Median target $130.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$709.18+$5.03 (+0.71%)
Thermo Fisher Scientific Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.38% below the high.
$236.94+$2.87 (+1.23%)
Danaher Corporation’s quoted price sits in the upper half of its reported 52-week range, 2.41% below the high.
$181.15-$0.33 (-0.18%)
Agilent Technologies, Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.01% below the high.
$480.07+$3.19 (+0.67%)
Waters Corporation’s quoted price sits in the upper half of its reported 52-week range, 0.46% below the high.
$1,718.61+$20.14 (+1.19%)
Mettler-Toledo International Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.58% below the high.
$376.10+$2.12 (+0.57%)
Charles River Laboratories International, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.93% below the high.
$72.71+$0.02 (+0.03%)
Bio-Techne Corporation’s quoted price sits in the upper half of its reported 52-week range, 0.05% below the high.
$50.34+$0.01 (+0.02%)
Qiagen N.V.’s quoted price sits in the upper half of its reported 52-week range, 12.94% below the high.
